Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Tempol (MBM-02) in Subjects With COVID-19 Infection

NCT04729595 is registered in ClinicalTrials.gov with Adamis Pharmaceuticals Corporation as lead sponsor.

NCT NCT04729595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04729595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Tempol (MBM-02) in Subjects With COVID-19 Infection
Lead sponsor
Adamis Pharmaceuticals Corporation
Phase
Phase 2/3
Overall status
Terminated
Start date
September 1, 2021
Completion date
September 21, 2022
Enrollment
248 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

covid19